Intuitive Surgical stock: BMO keeps Outperform rating on ASC growth
Published on 11/19/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBMO highlights outpatient robotics
- BMO Capital reaffirmed an Outperform rating and a 518 US dollar price target.
- The analyst cited a refurbished da Vinci Xi selection at an ambulatory surgery center.
- Intuitive Surgical's recent quarterly growth remains central to the analyst view.
Intuitive Surgical stock: BMO Capital reaffirmed its Outperform rating and 518 US dollar price target on November 17, 2026. The analyst action focused on the medical-device maker's opportunity in ambulatory surgery centers, or ASCs.
ASC demand supports the outlook
As Investing.com reported, BMO cited a discussion with an ASC administrator. The center selected a refurbished da Vinci Xi system after reviewing Medtronic's Hugo and Distalmotion's Dexter platforms.
BMO said the decision reflected surgeon familiarity, the breadth of procedures, service capabilities and Intuitive Surgical's product roadmap. The bank also said competing systems were not priced low enough to offset the adoption risk associated with a new platform.
What BMO sees next
BMO estimates that an ASC may need 140 to 150 procedures a year to support the economics of the Xi system. The firm sees further potential for system placements and procedure growth as more operations move into outpatient settings.
The analyst view also allows for centers to move toward da Vinci 5 systems as utilization and procedure complexity increase. That framework puts the ASC channel alongside Intuitive Surgical's established hospital business as an important area for future adoption.
Quarterly backdrop remains mixed
Investing.com reported that Intuitive Surgical's latest quarter generated 3.05 billion US dollars in revenue, above the cited consensus estimate of 2.91 billion US dollars. GAAP earnings per share were 1.49 US dollars after a 450 million US dollar litigation settlement, while Systems revenue reached 769 million US dollars against a cited estimate of 679 million US dollars.
The figures leave investors weighing strong revenue performance and procedure expansion against the effect of litigation costs and differing analyst views. BMO's unchanged rating signals a constructive stance on the company's outpatient robotics opportunity.
Current market reports provide the broader US trading context.
More news and analyses on Intuitive Surgical stock.
Intuitive Surgical at a glance
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Home exchange: Nasdaq
- Analyst action: BMO Capital reaffirmed Outperform and a 518 US dollar price target
- Event date: November 17, 2026
